Kiromic BioPharma (KRBP) Issues Business Update; Reports Q3 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Kiromic BioPharma Provides Business Update and Reports Third Quarter 2021 Financial Results
March 11, 2022 4:02 PM ESTQuarter Updates Include Companys Progress in the Following Areas:
Expansion of DIAMOND® AI Platform to More than 1.5 Billion Data Points
Completion of InSilico Solutions, LLC Acquisition
Closing of Public Offering
Addition of Key Personnel Across Bioinformatics, Clinical Translational, Manufacturing, and Operations
HOUSTON--(BUSINESS WIRE)-- Kiromic BioPharma, Inc. (NASDAQ: KRBP) (Kiromic or the Company), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND®... More
